NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses

Montserrat García‐Closas(National Cancer Institute), Núria Malats(Municipal Institute for Medical Research), Debra T. Silverman(National Cancer Institute), Mustafa Dosemeci(National Cancer Institute), Manolis Kogevinas(Municipal Institute for Medical Research), David W. Hein(University of Louisville), Adonina Tardón(Universidad de Oviedo), Cònsol Serra(Pompeu Fabra University), Alfredo Carrato(Hospital General Universitario de Elche), Reina García-Closas(Hospital Universitario de Canarias), Josep Lloreta(Municipal Institute for Medical Research), Gemma Castaño‐Vinyals(Municipal Institute for Medical Research), Meredith Yeager(National Cancer Institute), Robert Welch(National Cancer Institute), Stephen J. Chanock(National Cancer Institute), Nilanjan Chatterjee(National Cancer Institute), Sholom Wacholder(National Cancer Institute), Claudine Samanic(National Cancer Institute), Montserrat Torà(Municipal Institute for Medical Research), F. FERNÁNDEZ(Municipal Institute for Medical Research), Francisco X. Real(Pompeu Fabra University), Nathaniel Rothman(National Cancer Institute)
The Lancet
August 1, 2005
Cited by 630Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis